| Title |
Benzodiazepine Use and Risk of Developing Alzheimer’s Disease or Vascular Dementia: A Case–Control Analysis
|
|---|---|
| Published in |
Drug Safety, June 2015
|
| DOI | 10.1007/s40264-015-0319-3 |
| Pubmed ID | |
| Authors |
Patrick Imfeld, Michael Bodmer, Susan S. Jick, Christoph R. Meier |
| Abstract |
Previous observational studies have associated benzodiazepine use with an increased risk of dementia. However, limitations in the study methods leave questions unanswered regarding the interpretation of the findings. A case-control analysis was conducted using data from the UK-based Clinical Practice Research Datalink (CPRD). A total of 26,459 patients aged ≥65 years with newly diagnosed Alzheimer's disease (AD) or vascular dementia (VaD) between 1998 and 2013 were identified and matched 1:1 to dementia-free controls on age, sex, calendar time, general practice, and number of years of recorded history. Adjusted odds ratios (aORs) were calculated with 95 % confidence intervals (CIs) of developing AD or VaD in relation to previous benzodiazepine use, stratified by duration and benzodiazepine type. The aOR (95 % CI) of developing AD for those who started benzodiazepines <1 year before diagnosis was 2.20 (1.91-2.53), and fell to the null for those who started between 2 and <3 years before [aOR 0.99 (0.84-1.17)]. The aOR (95 % CI) of developing VaD for those who started benzodiazepines <1 year before diagnosis was 3.30 (2.78-3.92), and fell close to the null for those who started between 3 and <4 years before [aOR 1.16 (0.96-1.40)]. After accounting for benzodiazepine use initiated during this prodromal phase, long-term use of benzodiazepines was not associated with an increased risk of developing AD [aOR 0.69 (0.57-0.85)] or VaD [aOR 1.11 (0.85-1.45)]. After taking a prodromal phase into consideration, benzodiazepine use was not associated with an increased risk of developing AD or VaD. |
X Demographics
The data shown below were collected from the profiles of 24 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 2 | 8% |
| Japan | 2 | 8% |
| United Kingdom | 1 | 4% |
| Colombia | 1 | 4% |
| United States | 1 | 4% |
| Australia | 1 | 4% |
| Mexico | 1 | 4% |
| Spain | 1 | 4% |
| France | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 12 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 20 | 83% |
| Practitioners (doctors, other healthcare professionals) | 2 | 8% |
| Scientists | 2 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 111 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 109 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 20 | 18% |
| Other | 14 | 13% |
| Student > Ph. D. Student | 14 | 13% |
| Student > Bachelor | 10 | 9% |
| Student > Master | 8 | 7% |
| Other | 19 | 17% |
| Unknown | 26 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 34 | 31% |
| Pharmacology, Toxicology and Pharmaceutical Science | 19 | 17% |
| Neuroscience | 7 | 6% |
| Biochemistry, Genetics and Molecular Biology | 3 | 3% |
| Nursing and Health Professions | 3 | 3% |
| Other | 8 | 7% |
| Unknown | 37 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 32. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 May 2019.
All research outputs
#1,214,298
of 25,257,066 outputs
Outputs from Drug Safety
#100
of 1,804 outputs
Outputs of similar age
#14,479
of 269,189 outputs
Outputs of similar age from Drug Safety
#2
of 34 outputs
Altmetric has tracked 25,257,066 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,804 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.1. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 269,189 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.